British Columbia Extends Biosimilar Switching To Adalimumab

Follows Launch Of Five Humira Biosimilars In Canada In February

08 Apr 2021

British Columbia has expanded its biosimilar switching program to cover patients being treated with Humira in the Canadian province.

British Columbia Canada Flags — British Columbia is flying the flag for biosimilar switching in Canada • Source: Alamy

Patients being treated with Humira (adalimumab) in British Columbia will soon be switched to adalimumab biosimilars, after the Canadian province expanded its biosimilar switching program to cover the blockbuster biologic.

Almost two years ago, British Columbia launched its biosimilar switching program that saw patients being treated with etanercept, infliximab and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Iron Sucrose Competition Expands With Viatris and Amphastar FDA Approvals

12 Aug 2025

• By Dean Rudge

Viatris and Amphastar are expanding their complex generic portfolios with the planned launches of FDA-approved versions of Vifor Pharma/Daiichi Sankyo’s Venofer (iron sucrose). The FDA’s database also show Sandoz holds an approval for generic Venofer, though it has not disclosed launch plans.